Shares have been marching higher, with the stock up 2.4% over the past month. The stock hit a new 52-week high of $27.76 in the previous session. Progyny has gained 56.3% since the start of the year ...

CareDx, Inc. reports its first net profit in a decade with improved cash flow and margins. Click for this updated look at CDNA stock prospects.

Memory swizzling is the quiet tax that every hierarchical-memory accelerator pays. It is fundamental to how GPUs, TPUs, NPUs, ...

Derivatives North America (CDNA) has announced a strategic collaboration with ERShares and Signal Markets to develop a global ...

Fintel reports that on December 15, 2025, Wells Fargo maintained coverage of CareDx (NasdaqGM:CDNA) with a Equal-Weight ...

Eva Ados, Chief Investment Strategist and COO of ERShares, added, "As market complexity increases, investors need clearer signals, not more noise. This platform is designed to connect macroeconomic ...

CareDx (CDNA) has quietly staged a sharp rebound, with shares up roughly 11% over the past week and almost 29% in the past month, drawing fresh attention to its transplant diagnostics business. See ...

In addition to Craig-Hallum, CareDx also received a Buy from TR | OpenAI – 4o’s Cira Diagnissa in a report issued on November 10. However, on the same day, H.C. Wainwright reiterated a Hold rating on ...

Total Revenue: $100.1 million, up 21% year over year. Testing Services Revenue: $72.2 million, an increase of 19% year over year. Patient and Digital Solutions Revenue: $15.4 million, up 30% year over ...

This article first appeared on GuruFocus. CareDx Inc (NASDAQ:CDNA) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $95.25 million, and the earnings ...

CareDx is estimated to be 35% overvalued based on current share price of US$14.35 Our fair value estimate is 51% lower than CareDx's analyst price target of US$21.83 Today we'll do a simple run ...